GlassScriptPhysician profile
Brandy Story
NPI 1093212516
$17,764.78
in general payments reported to CMS, 2019-2025
57 companies · $4,140 in 2025
The $4,140 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,240 · 2022: $3,674 · 2023: $3,611 · 2024: $3,100 · 2025: $4,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $150 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,675.32 |
| Consulting Fee | $150.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,515.33 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $1,282.05 | 2021-2025 | |
| Neurelis, INC. | $1,036.92 | 2021-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $1,031.30 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $881.92 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $837.48 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Lundbeck LLC | $817.44 | 2021-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $674.99 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $600.56 | 2021-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $588.88 | 2021-2025 | Apokyn, Xadago, Apokyn |
| Genentech USA, INC. | $547.83 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $544.32 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Acadia Pharmaceuticals INC | $417.67 | 2021-2025 | Nuplazid |
| Pfizer INC. | $411.79 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $388.31 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Story listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.